Prevalence of Molecular Subtypes in Operated Cases of Breast Cancer and Its Clinicopathological Correlation: A Single Institute Study from a Tertiary Cancer Centre in North India

Jain, Sumeet; Narang, Vikram; Jain, Kunal; Paul, Davinder; Singh, Jagdeep; Sohi, Akashdeep Singh; Sood, Sandhya; Aggarwal, Ritu; Sood, Neena; Brar, Gagandeep

doi:10.1007/s13193-021-01374-w

Cited by 3 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Existem diversos estudos na literatura detalhando o perfil do carcinoma de mama [17][18][19][20][21] . Todos eles demonstram baixos percentuais de diagnóstico de câncer de mama entre mulheres com menos de 40 anos [17][18][19][20][21] 17,21 , o que se alinha com os achados do presente estudo. O carcinoma ductal foi evidenciado como o subtipo histológico predominante em todas as populações [17][18][19][20][21] .…”

Section: Discussionunclassified

“…Todos eles demonstram baixos percentuais de diagnóstico de câncer de mama entre mulheres com menos de 40 anos [17][18][19][20][21] 17,21 , o que se alinha com os achados do presente estudo. O carcinoma ductal foi evidenciado como o subtipo histológico predominante em todas as populações [17][18][19][20][21] . O carcinoma lobular apresentou prevalências significativamente baixas em todos os estudos, com apenas uma pesquisa relatando uma prevalência acima de 5% 19 .…”

Section: Discussionunclassified

“…Os estudos apresentaram discrepâncias quanto à classificação molecular. Três estudos indicaram prevalência do subtipo molecular Luminal-A 17,18,21 e dois relataram prevalência de Luminal-B 19,20 . Apenas um estudo indicou o subtipo Luminal-B HER-2 negativo como o mais prevalente 20 , assim como encontrado no presente estudo.…”

Section: Discussionunclassified

“…Três estudos indicaram prevalência do subtipo molecular Luminal-A 17,18,21 e dois relataram prevalência de Luminal-B 19,20 . Apenas um estudo indicou o subtipo Luminal-B HER-2 negativo como o mais prevalente 20 , assim como encontrado no presente estudo. Apenas dois estudos avaliaram a classificação molecular em pacientes com menos de 40 anos 20,21 .…”

Section: Discussionunclassified

“…Apenas um estudo indicou o subtipo Luminal-B HER-2 negativo como o mais prevalente 20 , assim como encontrado no presente estudo. Apenas dois estudos avaliaram a classificação molecular em pacientes com menos de 40 anos 20,21 . Em concordância com o presente estudo, Ushimado et al constataram que o subtipo Luminal-B HER-2 negativo foi o mais prevalente nessa faixa etária 21 .…”

Section: Discussionunclassified

See 4 more Smart Citations

Comparação do perfil imunohistoquímico entre mulheres com câncer de mama maiores de 40 e menores de 40 anos

Alves,

Nogueira,

Bagio

et al. 2024

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Objective: To compare immunohistochemical profiles, such as surrogate molecular classifications of breast carcinomas and histological findings, among women under and over 40 years of age. Methods: This was an observational, quantitative, and retrospective study based on data from the Instituto de Patologia de Araçatuba (IPAT), located in the countryside of the state of São Paulo, Brazil. Pathology reports from biopsy or surgical excision recorded between January 1, 2017, and June 30, 2020 (42 months) were reviewed. Only ductal and lobular carcinomas were histologically analyzed. Age, histological subtype, and immunohistochemical data of estrogen receptor, progesterone receptor, Her-2 and Ki-67 (< 20% x ≥ 20%) were analyzed. Specimens were categorized into two groups based on patient age at diagnosis (≤ 40 years vs. > 40 years). Results: There was no significant difference between the two age groups regarding hormone receptor, Her-2 evaluation, or histological classification (ductal vs. lobular). Nevertheless, breast cancer in younger women was associated with a higher Ki-67 index (p = 0.015). In the group aged 40 years and younger, half of the cases were classified as Luminal B-like, Her-2 negative, and 19% were triple-negative. For women over 40 years old, 57% were classified as luminal B-like, Her-2 negative, 9% were luminal A-like, and only 13% were triple-negative. Conclusion: The frequency of breast among young woman is substantial, and they tend to exhibit higher Ki-67 indexes.

show abstract

Section: Discussionunclassified

See 3 more Smart Citations

Comparação do perfil imunohistoquímico entre mulheres com câncer de mama maiores de 40 e menores de 40 anos

Alves,

Nogueira,

Bagio

et al. 2024

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

show abstract

Association of tumor volume with molecular phenotypes in breast cancer: A study at a tertiary care hospital

Sharma,

Singh,

Kumar

2024

World Acad Sci J

View full text Add to dashboard Cite

Breast cancer is a common cause of mortality among women worldwide. The incidence of this disease is higher in developing countries than in Western countries. Variations are noted in the distribution of breast cancer subtypes between Eastern and Western populations. Breast cancer is a heterogeneous lesion at the molecular level, and its prognosis is dependent on multiple factors. The present study aimed to determine the distribution of various molecular phenotypes of breast cancer and its association with tumor volume in patients presenting to a tertiary care hospital. The present observational cross-sectional study was conducted at a tertiary care medical college hospital. Following analysis using immunohistochemistry for estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and Ki67, all patients with breast cancer were classified into the luminal A, luminal B, HER2-enriched and triple-negative breast cancer (TNBC) groups. In addition, the age and tumor volume of the patients were compared among the different subtypes of breast cancer. Of the 165 patients with infiltrating ductal carcinoma (type not otherwise specified), the most common molecular phenotype was TNBC (39.4%), followed by luminal B (24.2%). The HER2-enriched and luminal A subtypes constituted 20.6 and 15.8%, respectively. There was no significant difference in the average age of the patients among the different molecular phenotypes. The smallest median tumor volume was observed in the luminal A (4.5 cm 3 ) group, followed by the HER2-enriched (8.0 cm 3 ), TNBC (24.0 cm 3 ) and luminal B (29.94 cm 3 ) groups. TNBC was the most common molecular phenotype. The tumor volume was the smallest in the patients with the luminal A subtype. As tumor volume has prognostic value, the poor prognosis of patients with TNBC and HER2-enriched breast cancer may be improved via targeted therapy. It is hoped that the findings of the present study may prove useful in the management of patients with breast cancer.

show abstract

An objective cross-sectional assessment of ChatGPT in hematology-oncology manuscript composition: Balancing promise with factual inaccuracies

Singh,

Prasad,

Joshi

et al. 2024

Cancer Research, Statistics, and Treatment

View full text Add to dashboard Cite

Background: Artificial intelligence (AI)-based large language models (LLMs), such as Chat Generative Pre-training Transformer (ChatGPT), exhibit promise in aiding manuscript composition and literature search, encompassing various research tasks. However, their utilization remains unregulated. Objectives: The primary objective of this study was to objectively assess the ability of ChatGPT 3.5 (free version) to assist with various tasks associated with manuscript preparation and research based on pre-defined scoring criteria. Secondary objectives included an assessment of the factual accuracy of data and any false information returned by ChatGPT. Materials and Methods: This cross-sectional study was planned in the Departments of Clinical Hematology and Medical Oncology of Dayanand Medical College and Hospital, Ludhiana, Punjab, India, a tertiary care referral center. Between July 1, 2023, and July 30, 2023, seven prompts comprising queries related to manuscript design, specific data, or complex discussion in hematology/oncology subjects were used. The responses were scored based on detailed pre-defined criteria for accuracy and completeness, and scoring was independently performed by a panel of five reviewers with current expertise in the field of hematology/medical oncology. Negative marking was performed for factual inaccuracies. Cronbach’s alpha and interclass correlation coefficient were calculated to assess inter-observer agreement. Results: ChatGPT readily provided information on the structural components of the manuscript and research design, with the ability to customize responses immediately. However, the presence of factual inaccuracies, fictional citations, and false information presented confidently were notable drawbacks. Cronbach’s alpha was 0.995, and the intraclass correlation coefficient was 0.995, indicating good inter-observer agreement. The overall score was 34.2 out of 90, with a poor score on the veracity of data and references. Conclusion: The current iteration of ChatGPT rapidly provides plausible and professional-looking information on up-to-date topics but is hindered by significant factual inaccuracies. Future research focusing on improving response accuracy and addressing ethical considerations of content generated by LLMs will help us maximize their potential in scientific paper development.

show abstract

Prevalence of Molecular Subtypes in Operated Cases of Breast Cancer and Its Clinicopathological Correlation: A Single Institute Study from a Tertiary Cancer Centre in North India

Cited by 3 publications

References 24 publications

Comparação do perfil imunohistoquímico entre mulheres com câncer de mama maiores de 40 e menores de 40 anos

Comparação do perfil imunohistoquímico entre mulheres com câncer de mama maiores de 40 e menores de 40 anos

Association of tumor volume with molecular phenotypes in breast cancer: A study at a tertiary care hospital

An objective cross-sectional assessment of ChatGPT in hematology-oncology manuscript composition: Balancing promise with factual inaccuracies

Contact Info

Product

Resources

About